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Abstract
Background: Vancomycin is increasingly administrated by
continuous infusion. But the treatment of patient in inten-
sive care need restricted volume to prevent fluid overload.
The aim of the study was to evaluate the physical and
chemical stability of solutions of a high concentration of
vancomycin hydrochloride in 5% glucose or 0.9% NaCl.
Methods: Eight syringes of 50mL, containing
41.66mg/mL of vancomycin hydrochloride four syringes
in 5% glucose and four in 0.9% NaCl were prepared and
stored at ambient temperature during 48h. Immediately
after preparation and during 48h, vancomycin hydrochlor-
ide concentrations were measured by a high-performance
liquid chromatography (HPLC). Spectrophotometric absor-
bance at different wavelengths, pH measurement and
microscopic observations were also performed.
Results: All solutions were physico-chemically stable
during the whole period storage at ambient temperature:
no color change, turbidity, precipitation or opacity, no
significant pH variations or optic densities were observed
in the solutions. Any crystals were seen by microscopic
analysis. Solutions are considered chemically stable as
the lower limit of the 95% unilateral confidence interval
on the mean remained above 90% of the initial concen-
tration for at least 48 h.
Conclusions: Solutions of vancomycin hydrochloride
41.66mg/mL in syringe of 5% glucose or 0.9% NaCl are
physically and chemically stable for at least 48 h when
stored in syringes at ambient temperature.
Keywords: vancomycin infusions, concentrated solutions,
high performance liquid chromatography, physicochem-
ical stability, syringe, intensive care units
Introduction
Vancomycin, a glycopeptide antibiotic, is often used as
antibiotherapy for hospitalized patients [1]. The most com-
mon usage of vancomycin is to treat methicillin-resistant
Staphylococcus aureus and epidermidis infections [2, 3]
and for patients who are allergic to penicillin and cepha-
losporin. A temporary association with aminoglycoside or
rifampicin can be used to obtain a synergic effect in case
of endocardite [3].
Vancomycin is increasingly administrated by contin-
uous infusions [4]. As reported in the literature, the infu-
sions of vancomycin (2.5 g/250mL) can be prepared by
the centralized intravenous admixture service (CIVAS)
[5–7] of the Pharmacy, according to the stability of the
solutions [8–21].
Vancomycin could also be infused by syringe, parti-
cularly in intensive care to reduce the perfusion volume.
Some data are available about this containers showing
that the syringes of low dose vancomycin can be stored at
4 °C for 6months [12] or at least 84 days [19] and once
brought to 25 °C it must be used within 48 h [12].
Nevertheless, the stability of high concentrated solutions
are not often investigated. Allen and Stiles [7] demon-
strated a stability for 96 h at room temperature for a
40mg/mL vancomycin while Barbault et al., a stability
of vancomycin eye drops at 50mg/mL for 15 days.
Furthemore, the production of vancomycin (GSK) was
stopped requiring the use of another supplier (Mylan). The
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stability of this new vancomycin was studied at 12.5mg/ml
but not at higher concentrations such as 40mg/mL.
The aim of the study is to determine the physical
and chemical stability of a higher concentration of van-
comycin hydrochloride (Mylan) (41.66mg/mL) in 5% glu-
cose or 0.9% NaCl solutions.
Materials and methods
Solution preparation
Commercially-available vancomycin hydrochloride solu-
tions (Vancomycine® 1 g Mylan, Hoeillart, Belgium lot
B2173) were prepared in a vertical laminar-airflow hood
with sterile water-for-injection (Baxter, Lessines, Belgium,
lot 14IO2T1E) as recommended by the manufacturers.
These solutions were added to polypropylene syringes
(Terumo, Haasrode, Belgium; lot 1412283) containing glu-
cose 5% (Baxter, Lessines, Belgium, lot15A14E46) or NaCl
0.9% (Baxter, Lessines, Belgium, lot14L01660) to obtain a
final volume of 48mL and then a 41.66mg/mL concentra-
tion solution. The syringes were stored at ambient tem-
perature, without protection from light.
Standard and quality control solutions
A standard solution of 0.5 g of vancomycin hydrochloride
(Vancomycine Mylan® Mylan, Hoeilaart, Belgium lot
B2174) were prepared in 10mL of purified water. This
50mg/mL solution was diluted in purified water to obtain
four standard solutions (40, 30, 20, 10 and 5mg/mL) and
two quality controls (40mg/mL and 10mg/mL)
Chromatographic conditions
As previously described [20], an Alliance Waters high-
performance liquid chromatographic (Alliance, model
2695, Waters Association, Milford, MA, USA) system was
used with a DAD detector (model 996, Waters Association)
and a data acquisition and processing module (Empower 2
Software, Waters Association, Milford, MA, USA).
A reversed phase column was used with associated
guard column (Prevail C18 5 µm 150mm×4.6mm, ref
99209 with Prevail guard column C18 7.5mm×4.6mm,
ref 99286, Alltech associates, Deerfield IL 60015).
The mobile phase was constituted of 15% acetoni-
trile (ref C03C11X, Lab-scan Ltd, Dublin, Ireland) and
85% KH2PO4 buffer (pH 3.00; 0.025M) (KH2PO4, ref
1.04873.1000, Merck, Darmstadt, Germany and H3PO4,
ref 10G090501, VWR International, Fontenay-sous-Bois,
France).
The flow rate was set at 1mL/min, the column tem-
perature at 35 °C, the Wavelenght (DAD detector) at
210 nm.
Validation of high-pressure liquid
chromatographic method [22]
Precision
Two control solutions of 10 and 40mg/mL of vancomy-
cin hydrochloride were undertaken in triplicate to cal-
culate the within (n = 10) and between (n = 9) day
reproducibility.
Linearity of analytical response
Linearity was evaluated by 7 dilutions of the solution
(2.5, 5, 10, 20, 30, 40, and 50mg/mL of vancomycin
hydrochloride) injected in triplicate.
Stability indication
The stability indicating capability of the chromatographic
method was assessed using decomposed solutions of
drugs. Degraded samples of vancomycin hydrochloride
were then assayed to confirm separation of the parent
antibiotic from its degradation products. Vancomycin
solutions at natural pH (3.72), alkaline pH (11.54) by
adding NaOH 5M (Merck, Darmstadt, Germany), and
acidic pH (1.60) by adding HCl 12M (Merck, Darmstad,
Germany) were heating at 100 °C during 30 and 60min.
Ten µL of these solutions was injected in the HPLC sys-
tem before and after heating.
Physical stability
Visual compatibility was defined as the absence of parti-
culate formation, haze, precipitation, color change and
gas evolution [23]. At each time of the study, various tests
were conducted to detect any particle contamination:
visual and microscopical inspection and optical density
measurements. The samples were then visually inspected
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with unaided eye, in front of a black and white back-
ground, the pellet obtained after centrifugation at 3000
rpm for 8min was observed with a microscope 10 × (Carl
Zeiss, Germany), looking for crystals.
The potential presence of subvisible particles was
investigated by spectrophotometry. The optical densi-
ties were then measured by a spectrophotometer
(Genesys 10 UV, Spectronic Unican) at 350 nm, 410 nm
and 550 nm [24].
The pH of the solutions were measured with a pH-
meter (Inolab WTW Weilhein, Germany) equipped with a
glass electrode (Biotrode Hamilton Bonaduz, Switzerland)
calibrated with two standard solutions at pH4 and pH7
(CertiPur, Merck, Darmstadt, Germany).
High-pressure liquid chromatographic assay
The five standard solutions, the two quality controls and
the samples were all diluted 40-fold and 10 µL of each
were injected into the chromatograph.
Results were automatically calculated by interpolation
of a five-level calibration curve (linear through zero), per-
formed by the Empower 2 software (Waters Association,
Milford, MA, USA) using peak areas versus standard
concentrations.
Stability study
Four syringes of 2 g infusion per 48mL in 5% glucose
and four syringes of the solutions in 0.9% NaCl were
prepared as described above and stored until 48 h at
ambient temperature (range: 18–25 °C). The concentra-
tions of vancomycin hydrochloride were determined in
triplicate for each of them immediately after prepara-
tion and after 2, 4, 6, 8, 22, 24, 26, 28, 30 and 48 h of
storage.
Statistical analysis
As recommended by the US Food and Drug
Administration, solutions were considered stable if the
95% one-sided lower confidence limit of the concentra-
tion remains superior to 90% of the initial concentration
[25] or 95% of the initial concentration when any signs of
physical instability exist [26].
Results
Validation of the method
The within and between-day repoducibilities realized on
two concentrations (40mg/mL and 10mg/mL) are shown
in Table 1 and could be considered as acceptable.
Linear-regression analysis of peak area yielded a deter-
mination coefficient r2 > 0.999 in the range of 2.5mg/mL
to 50mg/mL.
The degradation assay showed that the decomposi-
tion product peaks were resolved from the peak corre-
sponding to the intact drug in all conditions (Figure 1).
Physical stability
All solutions were physically stable during the whole
period storage at ambient temperature: no color change,
turbidity, precipitation or opacity, no significant variation
in pH values in 5% glucose (mean ± SD: 3.09 ± 0.01;
minimum: 3.07- maximum: 3.12) and in 0.9% NaCl
(mean ± SD: 3.17 ± 0.01; minimum: 3.15 –maximum:
3.19) or optical densities were observed in the solution.
Any crystals were seen by microscopic analysis.
Chemical stability
Concentrations of vancomycin hydrochloride during sto-
rage expressed as percentage of the initial dosage are
shown in Table 2. The concentrations of the solutions
remain stable with a lower confidence limit superior to
90% of the initial concentration until 48 h. They are no
difference between the solutions of 5% glucose and
0.9% sodium chloride.
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Figure 1: Chromatograms showing degradation test. (A) No heating at natural pH(3.72), at acidic pH(1.60) and at alkaline pH (11.54). (B)
Heating at 100 °C for 30min at natural pH(3.72), at acidic pH(1.60) and at alkaline pH (11.54). (C) Heating at 100 °C for 60min at natural pH
(3.72), at acidic pH(1.60) and at alkaline pH (11.54).
Table 2: Variation of the vancomycin hydrochloride concentrations.
Hours Vancomycin hydrochloride in Glucose % Vancomycin hydrochloride NaCl .%
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Discussion
Vancomycin is often used as antibiotherapy for hospita-
lized patients [1] and is increasingly administrated by
continuous infusions [4].
The total volume of infusion administrated to
patients admitted into intensive care units is often impor-
tant [27], the importance of fluid balance and the preven-
tion of fluid overload in many disease states remaining a
prevalent discussion in this unit [28]. One possible way to
avoid such type of adverse effects is to reduce the global
volume of infusion by using drugs solution within higher
concentrations. Concentrated solutions (2 g of vancomy-
cin in 48mL of solution) are then often needed to be
administrated to the critical ill or injured patients. High
concentrations of vancomycin being deleterious for
venous system, particularly in case of extravasation, the
solution must be administrated through a central line,
the most often present in hospitalized patients in inten-
sive care.
Data on the stability of a new commercial vancomy-
cin (Mylan, Hoeilaart, Belgium) were poorly investigated,
particularly for concentrated solutions [29, 30].
According to these results, solutions of vancomy-
cin hydrochloride (Mylan, Hoeillart, Belgium)
41.66mg/mL in 5% glucose or 0.9% NaCl are physi-
cally and chemically stable at least for 48 h when
stored in syringes at ambient temperature, without
protection from light. The final volume of 48mL was
preferred to 50mL as it adjusts easily the hourly flow
rate of the syringe pump.
These results are in accordance with previous results
with other manufacturers or solutions [8, 31, 32] adds to
the list of our systematic study of the chemical stability of
long-term intravenous medication solutions ready for
use [33].
Conclusion
According to this study, solutions of vancomycin hydro-
chloride 41.66mg/mL in 5% glucose or 0.9% NaCl are
physically and chemically stable at least for 48h when
stored in syringes at ambient temperature. This concentra-
tion may be used in ICU to treat patient and prevent fluid
overload.
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